Literature DB >> 14711361

Towards a vaccine against Ebola virus.

Thomas W Geisbert1, Peter B Jahrling.   

Abstract

Ebola virus infection causes hemorrhagic fever with high mortality rates in humans and nonhuman primates. Currently, there are no vaccines or therapies approved for human use. Outbreaks of Ebola virus have been infrequent, largely confined to remote locations in Africa and quarantine of sick patients has been effective in controlling epidemics. In the past, this small global market has generated little commercial interest for developing an Ebola virus vaccine. However, heightened awareness of bioterrorism advanced by the events surrounding September 11, 2001, concomitant with knowledge that the former Soviet Union was evaluating Ebola virus as a weapon, has dramatically changed perspectives regarding the need for a vaccine against Ebola virus. This review takes a brief historic look at attempts to develop an efficacious vaccine, provides an overview of current vaccine candidates and highlights strategies that have the greatest potential for commercial development.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14711361     DOI: 10.1586/14760584.2.6.777

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  17 in total

Review 1.  Advances in virus-like particle vaccines for filoviruses.

Authors:  Kelly L Warfield; M Javad Aman
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

2.  Filovirus emergence and vaccine development: a perspective for health care practitioners in travel medicine.

Authors:  Uzma N Sarwar; Sandra Sitar; Julie E Ledgerwood
Journal:  Travel Med Infect Dis       Date:  2010-06-26       Impact factor: 6.211

3.  A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial.

Authors:  Julie E Martin; Nancy J Sullivan; Mary E Enama; Ingelise J Gordon; Mario Roederer; Richard A Koup; Robert T Bailer; Bimal K Chakrabarti; Michael A Bailey; Phillip L Gomez; Charla A Andrews; Zoe Moodie; Lin Gu; Judith A Stein; Gary J Nabel; Barney S Graham
Journal:  Clin Vaccine Immunol       Date:  2006-09-20

4.  Ebolavirus glycoprotein structure and mechanism of entry.

Authors:  Jeffrey E Lee; Erica Ollmann Saphire
Journal:  Future Virol       Date:  2009       Impact factor: 1.831

5.  Stimulation of Ebola virus production from persistent infection through activation of the Ras/MAPK pathway.

Authors:  James E Strong; Gary Wong; Shane E Jones; Allen Grolla; Steven Theriault; Gary P Kobinger; Heinz Feldmann
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-03       Impact factor: 11.205

6.  Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species.

Authors:  Lisa E Hensley; Sabue Mulangu; Clement Asiedu; Joshua Johnson; Anna N Honko; Daphne Stanley; Giulia Fabozzi; Stuart T Nichol; Thomas G Ksiazek; Pierre E Rollin; Victoria Wahl-Jensen; Michael Bailey; Peter B Jahrling; Mario Roederer; Richard A Koup; Nancy J Sullivan
Journal:  PLoS Pathog       Date:  2010-05-20       Impact factor: 6.823

7.  Evaluation of Different Strategies for Post-Exposure Treatment of Ebola Virus Infection in Rodents.

Authors:  Jason S Richardson; Gary Wong; Stéphane Pillet; Samantha Schindle; Jane Ennis; Jeffrey Turner; James E Strong; Gary P Kobinger
Journal:  J Bioterror Biodef       Date:  2011-10-20

8.  Development of RNA aptamers targeting Ebola virus VP35.

Authors:  Jennifer M Binning; Tianjiao Wang; Priya Luthra; Reed S Shabman; Dominika M Borek; Gai Liu; Wei Xu; Daisy W Leung; Christopher F Basler; Gaya K Amarasinghe
Journal:  Biochemistry       Date:  2013-11-14       Impact factor: 3.162

9.  A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge.

Authors:  Alexander Bukreyev; Lijuan Yang; Sherif R Zaki; Wun-Ju Shieh; Pierre E Rollin; Brian R Murphy; Peter L Collins; Anthony Sanchez
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

10.  Successful topical respiratory tract immunization of primates against Ebola virus.

Authors:  Alexander Bukreyev; Pierre E Rollin; Mallory K Tate; Lijuan Yang; Sherif R Zaki; Wun-Ju Shieh; Brian R Murphy; Peter L Collins; Anthony Sanchez
Journal:  J Virol       Date:  2007-04-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.